The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer - PubMed (original) (raw)
. 2009 May 15;115(10):2063-70.
doi: 10.1002/cncr.24254.
Affiliations
- PMID: 19298008
- DOI: 10.1002/cncr.24254
Free article
The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer
David Horst et al. Cancer. 2009.
Free article
Abstract
Background: Most colon cancers harbor mutations of APC or beta-catenin, both of which may lead to nuclear beta-catenin accumulation in the tumor cells and constitutively activated expression of its target genes. In many colon cancers, however, nuclear beta-catenin accumulation is heterogeneous throughout the tumor and often confined to the tumor margin. Herein, the authors investigated whether the intratumoral distribution of nuclear beta-catenin can serve as a prognostic marker for survival and tumor progression of stage IIA colon cancer patients.
Methods: In total, 142 patients with primarily resected, moderately differentiated stage IIA colon cancer were included in this study. The patterning of nuclear beta-catenin expression was evaluated on immunohistochemically stained whole tissue sections of the tumors and was correlated with cancer-specific survival and disease-free survival using univariate and multivariate statistical analyses.
Results: Four distinct patterns of nuclear beta-catenin expression were identified, and 2 main categories comprising tumors with or without intratumoral regulation of nuclear beta-catenin were distinguished. Moreover, the results demonstrated that the patterning, and especially the regulation or absence of regulation of nuclear beta-catenin expression, was a strong predictive marker of patient survival and tumor progression.
Conclusions: The current results indicated that the distribution of nuclear beta-catenin expression can be used as a good prognostic marker in patients with stage IIA colon cancer. Thus, the evaluation of nuclear beta-catenin may help to identify patients who will have a shorter than average survival and patients with a greater risk of disease progression who may be considered for adjuvant therapeutic modalities and intensified clinical aftercare in the future.
Similar articles
- Mechanisms of oncogenesis in colon versus rectal cancer.
Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, Moriya Y, van de Velde CJ, van Krieken JH. Kapiteijn E, et al. J Pathol. 2001 Sep;195(2):171-8. doi: 10.1002/path.918. J Pathol. 2001. PMID: 11592095 - L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer.
Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW, Moon HY. Boo YJ, et al. Ann Surg Oncol. 2007 May;14(5):1703-11. doi: 10.1245/s10434-006-9281-8. Epub 2007 Jan 9. Ann Surg Oncol. 2007. PMID: 17211730 - Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer.
Poincloux L, Durando X, Seitz JF, Thivat E, Bardou VJ, Giovannini MH, Parriaux D, Barriere N, Giovannini M, Delpero JR, Monges G. Poincloux L, et al. Surg Oncol. 2009 Dec;18(4):357-65. doi: 10.1016/j.suronc.2008.09.003. Epub 2008 Nov 21. Surg Oncol. 2009. PMID: 19027288 Review. - Pediatric aggressive fibromatosis of the head and neck: a 20-year retrospective review.
Sharma A, Ngan BY, Sándor GK, Campisi P, Forte V. Sharma A, et al. J Pediatr Surg. 2008 Sep;43(9):1596-604. doi: 10.1016/j.jpedsurg.2008.02.001. J Pediatr Surg. 2008. PMID: 18778992 Review.
Cited by
- Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.
Wangefjord S, Brändstedt J, Lindquist KE, Nodin B, Jirström K, Eberhard J. Wangefjord S, et al. Diagn Pathol. 2013 Jan 21;8:10. doi: 10.1186/1746-1596-8-10. Diagn Pathol. 2013. PMID: 23337059 Free PMC article. - Wnts and the hallmarks of cancer.
Zhong Z, Yu J, Virshup DM, Madan B. Zhong Z, et al. Cancer Metastasis Rev. 2020 Sep;39(3):625-645. doi: 10.1007/s10555-020-09887-6. Cancer Metastasis Rev. 2020. PMID: 32385713 Review. - Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer.
Piulats JM, Kondo J, Endo H, Ono H, Hagihara T, Okuyama H, Nishizawa Y, Tomita Y, Ohue M, Okita K, Oyama H, Bono H, Masuko T, Inoue M. Piulats JM, et al. Oncotarget. 2018 Mar 23;9(22):15968-15983. doi: 10.18632/oncotarget.24641. eCollection 2018 Mar 23. Oncotarget. 2018. PMID: 29662620 Free PMC article. - Investigation of β-catenin and E-cadherin expression in Dukes B2 stage colorectal cancer with tissue microarray method. Is it a marker of metastatic potential in rectal cancer?
Tóth L, András C, Molnár C, Tanyi M, Csiki Z, Molnár P, Szántó J. Tóth L, et al. Pathol Oncol Res. 2012 Apr;18(2):429-37. doi: 10.1007/s12253-011-9463-y. Pathol Oncol Res. 2012. PMID: 21975680 - Inflammation and colorectal cancer, when microbiota-host mutualism breaks.
Candela M, Turroni S, Biagi E, Carbonero F, Rampelli S, Fiorentini C, Brigidi P. Candela M, et al. World J Gastroenterol. 2014 Jan 28;20(4):908-22. doi: 10.3748/wjg.v20.i4.908. World J Gastroenterol. 2014. PMID: 24574765 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources